JANSSEN
28.4.2022 14:54:06 CEST | Business Wire | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual action tablet (DAT)* plus prednisolone, for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR)+ gene alterations. When approved by the European Commission, niraparib in combination with AAP will be the first dual action tablet formulation in the European Union specifically targeting HRR gene alterations in mCRPC.
The combination of niraparib, a PARP (poly adenosine diphosphate-ribose polymerase) inhibitor, and abiraterone acetate, a CYP17 inhibitor, targets two oncogenic drivers in patients with mCRPC, AR-axis and HRR gene alterations. The DAT formulation is also intended to be more convenient for patients, and thus aims to improve treatment compliance. Prostate cancer is one of the most common cancers in Europe with approximately 473,000 patients diagnosed in 2020.2 Up to approximately 30% of patients with mCRPC have HRR gene alterations which are associated with a worse prognosis compared to patients without HRR gene alterations.1
“People with prostate cancer harbouring BRCA alterations face a more aggressive form of disease with worse outcomes and faster progression, sadly leading to a shorter life expectancy,” commented Professor Gerhardt Attard= , Primary Study Investigator and Clinician Scientist and Team Leader at University College London Cancer Institute. “This submission is an important step towards improving the outcomes for people with metastatic prostate cancer harbouring BRCA alterations using a targeted therapy that significantly delays the time to their cancer progressing.”
The EU MAA is supported by data from the MAGNITUDE study (NCT03748641), a Phase 3, randomised, double-blind, placebo-controlled, multicentre study evaluating the safety and efficacy of niraparib combined with abiraterone acetate plus prednisone (AAP) in patients with mCRPC. The study showed that at the final analysis for radiographic progression-free survival (rPFS), the treatment combination of niraparib and AAP demonstrated a statistically significant improvement in patients with HRR gene alterations as compared to placebo and AAP.1 First results from the study were presented at the American Society of Clinical Oncology – Genitourinary Cancers Symposium (ASCO GU 2022) Annual Meeting (Abstract #12). The study continues to collect data on the secondary endpoints, which include time-to-initiation of cytotoxic chemotherapy, time to symptomatic progression and overall survival.1
“The data supporting this submission demonstrate the benefit of niraparib in combination with AAP in patients with specific gene alterations and reinforce the importance of biomarker testing in helping to provide an individualised treatment for these patients,” said Kiran Patel, M.D., Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. “We are committed to advancing targeted therapeutic options for patients with prostate cancer as we build upon our deep understanding of the disease, with a focus on improving outcomes for patients.”
“The submission of niraparib in combination with AAP to the European Medicines Agency marks an important milestone in addressing specific genetic alterations in prostate cancer,” said Mathai Mammen, M.D., Ph.D., Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson. “We are determined to transform this complex disease through innovation, science and ingenuity.”
###
About Niraparib
Niraparib is an orally administered, selective poly-ADP ribose polymerase (PARP) inhibitor, that is currently being studied by Janssen for the treatment of patients with prostate cancer.1
Additional ongoing studies include the Phase 3 AMPLITUDE
study evaluating the combination of niraparib and AAP in a biomarker-selected patient population with metastatic hormone-sensitive prostate cancer (mHSPC).3
In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GSK in 2018), for exclusive rights to niraparib in prostate cancer. In the European Union, niraparib is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy (Zejula SmPC 2021). Niraparib is currently marketed by GSK as ZEJULA® .4
About abiraterone acetate
Abiraterone acetate is an orally-administered androgen biosynthesis inhibitor. In the European Union, abiraterone acetate is indicated with prednisone or prednisolone for the treatment of newly diagnosed high risk mHSPC in adult men in combination with ADT; the treatment of mCRPC in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated; and the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen (ZYTIGA SmPC 2020).5
Abiraterone acetate is currently marketed by Janssen Janssen-Cilag International NV as ZYTIGA® .5
About Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) characterises cancer that no longer responds to ADT and has spread to other parts of the body. The most common metastatic sites are bones, followed by lungs and liver.6
Prostate cancer is the most common cancer in men in Europe.7
More than one million men around the world are diagnosed with prostate cancer each year.8
Patients with mCRPC and HRR gene alterations have a worse prognosis than those without HRR alterations.9
About MAGNITUDE
MAGNITUDE (NCT03748641
) is a Phase 3 randomised, double-blind, placebo-controlled, multicentre clinical study evaluating the safety and efficacy of the combination of niraparib and AAP for patients with mCRPC, with or without certain HRR gene alterations. The study includes two cohorts in which patients were randomised to receive either niraparib and AAP or placebo and AAP cohorts: one cohort of patients with predefined HRR gene alterations (including ATM, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2 alterations) and one cohort of patients without HRR gene alterations. In a third, open-label cohort, all patients received the dual action tablet formulation of niraparib and AAP.1
The primary endpoint of the MAGNITUDE trial is rPFS. Secondary endpoints include time-to-initiation of cytotoxic chemotherapy, time to symptomatic progression and overall survival.1
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.
Learn more at www.janssen.com/emea/ . Follow us at www.twitter.com/JanssenEMEA for our latest news. Janssen Research & Development, LLC; Janssen-Cilag, S.A.; and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of niraparib. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., or any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov
, www.jnj.com
or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
# # #
*
DAT is a single tablet combining niraparib and
abiraterone acetate
+
HRR gene alterations include Ataxia Telangiectasia (ATM), breast cancer gene 1 and 2 (BRCA1/BRCA2), BRCA1 interacting protein 1 (BRIP1), cyclin-dependent kinase 12 (CDK12), Checkpoint Kinase 2 (CHEK2), fanconi anaemia (FANCA), Histone Deacetylase 2 (HDAC2) and partner and localiser of BRCA 2 (PALB2).
=
Professor Attard has served as a consultant to Janssen; he has not been paid for any media work.
References
1
Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. ASCO GU 2022.
2
International Agency for Research on Cancer. WHO. 2020. Available at: https://gco.iarc.fr/today/online-analysis-pie
. Last Accessed April 2022
3
Clinical Trials.Gov. A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration Sensitive Prostate Cancer (mCSPC) (AMPLITUDE). Available at: https://clinicaltrials.gov/ct2/show/NCT04497844
. Last accessed April 2022
4
European Medicines Agency. Zejula (Niraparib) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_en.pdf
. Last accessed April 2022.
5
European Medicines Agency. Zytiga (abiraterone acetate) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf
. Last accessed April 2022.
6
Cancer.org. Understanding advanced cancer, metastatic cancer, and bone metastasis. https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/what-is.html
. Last accessed April 2022.
7
HEAL. Men Prostate cancer. Available at: https://www.env-health.org/IMG/pdf/prostate_testical.pdf
. Last accessed April 2022
8
World Health Organization. "Globocan 2012: Prostate Cancer: Incidence, Mortality and Prevalence Worldwide, 2012." http://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-19.pdf
. Last accessed April 2022.
9
Castro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol
. 2019;37(6):490-503. doi:10.1200/JCO.18.00358
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005637/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Reports Third Quarter 2026 Results17.11.2026 13:45:00 CET | Press release
Klarna Group plc (NYSE: KLAR), the everyday finance network, today reported third quarter 2026 results. GMV reached $36.1 billion (+10% YoY), revenue $1.0 billion (+12% YoY), transaction margin dollars (TMD) $371 million (+32% YoY), and adjusted operating income $21 million (+$35m YoY). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116206092/en/ "Q3 was our fourth straight quarter with revenue above 1 billion dollars and positive adjusted operating income. We are keeping more of each dollar we process through our everyday finance network: transaction margin is now 37% of revenue, up from 31% a year ago. Looking ahead, we’re finishing the year strong as we are running on track with, or ahead of, all our full year outlook.” Sebastian Siemiatkowski, CEO & Co-Founder, Klarna Klarna’s full earnings release is available at the Quarterly Results section of its website at https://investors.klarna.com/financials/quarterly-results
Would You Let AI Manage Your Next Trip?17.11.2026 13:06:00 CET | Press release
New research suggests AI agents could change how travelers choose airlines and hotels by 2032The Intelligent Journey 2032 explores four directions travel could take by early in the next decade, and how technology, particularly AI, will connect travelers with airlines, airports, hotels and other travel companies.The study suggests the future will be defined by travelers deciding what they are willing to delegate, with clear consent, spending limits, and the ability to retain control as key considerations.It also identifies travel orchestration as the strategic prize for the industry, as AI could reshape travel commerce, and shift value toward those able to coordinate the entire journey across suppliers, payments, identity, disruption and service. AI is already transforming the traveler journey, helping people discover, plan and navigate their trips. The question is how far travelers will let AI make decisions for them in the future: booking, paying, changing plans and recovering from di
Iconic Raises $10M to Build Software That Understands the World’s Biggest Projects17.11.2026 13:01:00 CET | Press release
Iconic has raised $10 million in seed funding led by Peak Capital, with participation from Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. Since its founding in mid-2025, Iconic has signed five clients in energy, infrastructure, and AI infrastructure: a global energy major, a leading European utility, a major European airport, a European rail infrastructure owner, and a global contractor building semiconductor fabs and data centers. Each spends over $1 billion annually on capital projects. An estimated $15 trillion is invested in capital projects annually, yet fewer than 3% are delivered on time, on budget, and to plan. Capital projects rarely fail because of engineering complexity, but because decisions are made without a complete understanding of the project. Information is fragmented across documents and systems shared by owners, contractors, and engineering firms. Decisions are hard to reverse, with consequences lasting years through delays, claims, and cost
Quaise Energy Signs 50 MW Geothermal Power Purchase Agreement with Google17.11.2026 12:50:00 CET | Press release
Agreement advances development of commercial-scale superhot geothermal, will supply carbon-free energy to Oregon communities as early as 2030 Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that Google has signed a power purchase agreement (PPA) for 50 megawatts (MW) of superhot geothermal power from Project Obsidian, Quaise’s flagship project in Central Oregon. Once online, this always-on, carbon-free energy is slated to support Google’s existing data center operations in The Dalles, Ore. and the region’s communities. The agreement will help catalyze the commercial development of superhot geothermal energy, providing benefits for ratepayers and helping protect the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117923219/en/ Beginning as early as 2030, Google will purchase 50 MW of power from Project Obsidian. The initial phase of development will use convention
Nowhere to Sit, Nothing to Do: Europe’s Biggest Airports Fall Short for Passengers17.11.2026 12:24:00 CET | Press release
AirHelp data shows that nearly half of Europe’s biggest airports score below the global average for both seating and entertainment. One in four of Europe’s 50 biggest airports scores below the global average on all four parts of the experience passengers rated, according to AirHelp data covering 279 airports worldwide. Passengers rated each airport on wait times, restaurants, seating and entertainment. Twelve airports, including Dublin, Manchester, Lisbon, London Luton and Milan Bergamo, came in below the global average on all four. Only four beat all four averages: Zurich, Warsaw, Naples and Ankara. Entertainment is the weak spot almost everywhere Entertainment was the lowest-rated part of the experience at 45 of the 50 airports, averaging 6.5 out of 10, with more than half of the airports falling below the global average of 6.7. Seven airports scored less than 6, including Manchester, Stansted, Dublin and Oslo. The data also suggests that passengers who can’t find a seat usually have
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
